Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.

Abstract

The aim of the current study is to evaluate the prognostic value of anemia, an easily estimable parameter in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy. A total of 157 patients with newly diagnosed diffuse large B-cell lymphoma treated with ≥1 cycle of R-CHOP were included. Hemoglobin level without red cell transfusion within 7 days of initiation of treatment was chosen as a parameter of baseline cancer-induced anemia. To investigate the clinical significance of chemotherapy-induced anemia and its recovery after completion of treatment, 87 patients in complete remission for ≥6 months from the time of the last cycle of R-CHOP were grouped and analyzed separately. Patients with a cancer-induced anemia of hemoglobin <10 g/dL showed inferior event-free and disease-free survival compared to those with hemoglobin ≥10 g/dL. This finding was observed irrespective of the status of pre-treatment bone marrow involvement. In multivariate analysis, hemoglobin <10 g/dL was found to be an international prognostic index-independent prognostic factor. Risk of relapse was significantly higher for patients who were still anemic at 6 months after R-CHOP, compared to those who achieved complete recovery from chemotherapy-induced anemia within 6 months.

• Authors: Junshik Hong, Hyun Seon Woo, Hyunchul Kim, Hee Kyung Ahn, Sun Jin Sym, Jinny Park, Jeong Yeal Ahn, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
• Journal: Cancer science (Cancer Sci) Vol. 105 Issue 12 Pg. 1569-75 (Dec 2014) ISSN: 1349-7006 [Electronic] England
• PMID: 25263825 (Publication Type: Journal Article)
• Copyright: © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Biomarkers, Tumor
• R-CHOP protocol
• Rituximab
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Adult
• Aged
• Aged, 80 and over
• Anemia (blood, chemically induced, complications)
• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers, Tumor (blood)
• Cyclophosphamide (therapeutic use)
• Disease-Free Survival
• Doxorubicin (therapeutic use)
• Female
• Humans
• Lymphoma, Large B-Cell, Diffuse (blood, drug therapy, pathology)
• Male
• Middle Aged
• Multivariate Analysis
• Neoplasm Recurrence, Local (blood, diagnosis)
• Prednisone (therapeutic use)
• Rituximab
• Treatment Outcome
• Vincristine (therapeutic use)
• Young Adult